Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) EBT (2016 - 2025)

Vanda Pharmaceuticals' EBT history spans 16 years, with the latest figure at -$38.0 million for Q4 2025.

  • For Q4 2025, EBT fell 484.92% year-over-year to -$38.0 million; the TTM value through Dec 2025 reached -$138.6 million, down 504.89%, while the annual FY2025 figure was -$138.6 million, 504.89% down from the prior year.
  • EBT for Q4 2025 was -$38.0 million at Vanda Pharmaceuticals, down from -$28.4 million in the prior quarter.
  • Across five years, EBT topped out at $12.6 million in Q2 2021 and bottomed at -$38.0 million in Q4 2025.
  • The 5-year median for EBT is -$890500.0 (2023), against an average of -$5.1 million.
  • The largest annual shift saw EBT soared 740.29% in 2021 before it plummeted 5103.33% in 2024.
  • A 5-year view of EBT shows it stood at $8.6 million in 2021, then grew by 11.65% to $9.6 million in 2022, then tumbled by 117.28% to -$1.7 million in 2023, then tumbled by 291.15% to -$6.5 million in 2024, then crashed by 484.92% to -$38.0 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's EBT are -$38.0 million (Q4 2025), -$28.4 million (Q3 2025), and -$34.9 million (Q2 2025).